Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostics tests as well as the accuracy of drug delivery for infectious diseases and oncology.
Novosanis is a Belgian privately-held ISO13485 certified company endorsed on multiple occasions nationally and internationally for its solutions.
Novosanis prospers in user-friendly and game-changing medical devices meeting all regulatory and quality requirements for self-sampling and drug delivery solutions that improve accuracy and standardization while making handling easier, more consistent and more comfortable for the user.
We have two device platforms in portfolio:
Colli-Pee is a patented sampling device suited for standardized and volumetric collection of first-void urine (first 20ml of the urine flow) allowing improved detection of infectious diseases as well as early stage cancer. Colli-Pee is CE-marked and FDA listed.
VAX-ID is a patented and proven platform of injection devices suited for accurate drug delivery of e.g. therapeutic, prophylactic and allergy drugs and vaccines in the dermal layer of the skin.
A story of multidisciplinary collaborations
On the 12th of March 2013, Novosanis was founded as a spin-off company from the University of Antwerp. Novosanis is funded by a private investor Taste Invest next to subsidies from the Flemish Government and the European Commission. At present, two medical device platforms are being offered: VAX-ID - a platform of injection devices suited for accurate intradermal drug delivery - and Colli-Pee - a platform of self-sampling devices for volumetric and standarized collection of first-void urine.
The creation of these two devices, which are the heart of our company, was the result of multidisciplinary collaborations between the University of Antwerp (VAXINFECTIO and Product Development; formerly Artesis University College) and Voxdale (Design & Engineering company).
In September 2010, master student Wouter Coemans (Product Development) started working on the VAX-ID (formerly ‘Vaxintradermal’) project in the context of his thesis. The idea for an intradermal vaccination device resulted from VAXINFECTIO's key researchers that identified the lack of sufficient vaccine during the pandemic H1N1 flu. Intradermal vaccination allows for smaller volumes while leading to an improved immune response. An accurate and user-friendly was a clear unmet medical need. That year, Koen Beyers, CEO of Voxdale - a design and engineering company based in Antwerp - and currently also CTO of Novosanis, became involved in the creation of the VAX-ID by being Wouter Coemans’ industrial supervisor. In 2011, the VAX-ID project was continued by three master students with different backgrounds: Ruben Camerlynck (Product Development), Charlotte Reypens (Applied Economics) and Timothi Van Mulder (Nursing and Obstetrics), who investigated the industrial design, clinical applicability and market potential of the device, respectively. For their work, all three of them were awarded by BiR&D (Belgian Industrial Research and Development). Vanessa Vankerckhoven, at that time appointed as Innovation Manager at VAXINFECTIO, and currently CEO of Novosanis, coordinated the VAX-ID project and was responsible for academic supervision and support for all students involved. Timothi Van Mulder is now appointed Clinical Affairs Manager and Quality Manager. He's also pursuing a PhD (Baekeland) on research into drug delivery devices for paedriatic applications.
In September 2011, master student Lara Biekens (Product Development) started developing a device for non-invasive collection of first-void urine, now known as the Colli-Pee (formerly ‘2Pi’). The concept was inspired by VAXINFECTIO’s researchers: having discovered that first-void urine can be used for the detection of HPV infection, they looked for a device to allow for non-invasive collection of first-void urine. In 2012, this project was, similarly to the VAX-ID project, continued by three master students with different backgrounds: Hanne De Bauw (Product Development), Tina Van Hove (Nursing and Obstetrics) and Ragnar Dienske (Sociology), who each focused on a different part of the development process. Hanne De Bauw’s work was supervised by Koen Beyers and his Voxdale team, while Tina Van Hove’s research was supervised by Timothi Van Mulder. Again, Vanessa Vankerckhoven was responsible for coordination, academic supervision and support for all students involved in the Colli-Pee project.
Novosanis: for a healthy life
In 2013, it was clear that both Colli-Pee and VAX-ID had market potential and a good business case, although additional R&D would be needed. Soon, both devices formed the initial portfolio of Novosanis: a newly founded spin-off company from the University of Antwerp, focusing on design and development of innovative medical devices. Vanessa Vankerckhoven, who coordinated both the VAX-ID and the Colli-Pee project from her position as research & innovation manager at VAXINFECTIO, was appointed Chief Executive Officer, whereas Koen Beyers, involved in the design of both devices, became Chief Technical Officer. Novosanis is now a medical device company with an innovative approach and a bright future, striving for a healthy life for everyone.
Novosanis: wholly owned subsidiary of OraSure Technologies Inc.
On January 5, 2019 became a wholly owned subsidiary of OraSure Technologies Inc., a publicly traded company based in Bethlehem, PA, US (NASDAQ: OSUR) and a leader in point of care diagnostic tests, sample collection and stabilization devices. Novosanis’ urine collection technology, Colli-Pee, expands molecular collection portfolio and advances OraSure’s expertise in non-invasive sampling.
Read the press release.
Our quality policy states: "Novosanis prospers in user-friendly medical device solutions for self-sampling and drug delivery that improve accuracy, standardization and overall patient comfort. Novosanis maintains a quality management system in accordance to ISO13485 and all applicable regulatory requirements. Effectiveness is continuously assessed and improved. Co-workers are encouraged to exceed the Novosanis quality objectives which is empowered by adequate training and resources."
Novosanis received its ISO13485 certificate in May 2016. Read more here.
Our team consists of seasoned experts in (bio) medical sciences, product design, (biomedical) engineering, clinical affairs, business development, sales, marketing, communication, quality, regulatory affairs and manufacturing (production).
Are you interested in joining forces with our team? You can find all information on job opportunities and internships here.